Loading...
XSHE300529
Market cap3.18bUSD
Jan 17, Last price  
29.65CNY
1D
3.02%
1Q
-5.72%
Jan 2017
-37.00%
IPO
73.29%
Name

Jafron Biomedical Co Ltd

Chart & Performance

D1W1MN
XSHE:300529 chart
P/E
53.40
P/S
12.13
EPS
0.56
Div Yield, %
2.41%
Shrs. gr., 5y
0.16%
Rev. gr., 5y
13.59%
Revenues
1.92b
-22.84%
194,982,813250,620,619303,587,592370,937,549508,905,176543,640,521718,491,1311,016,508,7921,431,819,3901,950,780,4902,675,454,4602,491,439,4321,922,348,169
Net income
436m
-50.93%
75,762,073100,024,289126,784,553160,048,195200,441,034202,118,491284,413,992401,979,957570,822,715875,240,5361,196,813,354889,564,381436,492,212
CFO
917m
+3.73%
77,061,800120,249,700133,325,812137,354,216205,178,111178,635,457304,095,588384,076,786583,495,276957,488,7701,249,414,597883,800,425916,743,866
Dividend
May 31, 20240.4 CNY/sh
Earnings
May 20, 2025

Profile

Jafron Biomedical Co.,Ltd. engages in the research, development, production, and marketing of biological materials and medical devices in China. It offers solutions for kidney, liver, critical, and rheumatism diseases, as well as poisoning; adsorption products and blood purification machines; and other products, such as single use arteriovenous puncture, hemodialysis online dry powder bags/cylinders, disinfectants, hemodialysis concentrates, and medical adsorbable suture with needles. The company offers its products in Germany, Italy, Turkey, Thailand, Vietnam, the Philippines, South Africa, Kenya, Chile, Peru, and the United Arab Emirates. Jafron Biomedical Co.,Ltd. was founded in 1989 and is based in Zhuhai, China.
URL
https://www.jafron.com/
IPO date
Aug 02, 2016
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,922,348
-22.84%
2,491,439
-6.88%
Cost of revenue
1,293,786
1,427,007
Unusual Expense (Income)
NOPBT
628,563
1,064,432
NOPBT Margin
32.70%
42.72%
Operating Taxes
95,297
135,890
Tax Rate
15.16%
12.77%
NOPAT
533,266
928,543
Net income
436,492
-50.93%
889,564
-25.67%
Dividends
(561,786)
(716,985)
Dividend yield
3.18%
2.90%
Proceeds from repurchase of equity
(382,583)
(5,192)
BB yield
2.17%
0.02%
Debt
Debt current
261,830
321,818
Long-term debt
1,403,798
971,471
Deferred revenue
151,783
151,656
Other long-term liabilities
(936,783)
Net debt
(1,260,795)
(1,334,912)
Cash flow
Cash from operating activities
916,744
883,800
CAPEX
(247,253)
Cash from investing activities
(249,649)
Cash from financing activities
(451,911)
FCF
773,780
393,141
Balance
Cash
2,810,294
2,558,755
Long term investments
116,129
69,445
Excess cash
2,830,306
2,503,629
Stockholders' equity
3,367,589
2,926,540
Invested Capital
2,128,631
1,526,633
ROIC
29.18%
52.89%
ROCE
12.63%
21.43%
EV
Common stock shares outstanding
793,622
797,823
Price
22.23
-28.22%
30.97
-41.89%
Market cap
17,642,222
-28.60%
24,708,586
-42.29%
EV
16,386,826
23,394,844
EBITDA
723,355
1,138,427
EV/EBITDA
22.65
20.55
Interest
55,287
36,044
Interest/NOPBT
8.80%
3.39%